{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T18:06:58Z","timestamp":1776276418942,"version":"3.50.1"},"reference-count":9,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,10,4]],"date-time":"2018-10-04T00:00:00Z","timestamp":1538611200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s40259-018-0310-5","type":"journal-article","created":{"date-parts":[[2018,10,4]],"date-time":"2018-10-04T03:37:50Z","timestamp":1538624270000},"page":"639-642","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["PF-06438179\/GP1111: An Infliximab Biosimilar"],"prefix":"10.1007","volume":"32","author":[{"given":"Zaina T.","family":"Al-Salama","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,10,4]]},"reference":[{"key":"310_CR1","unstructured":"European Medicines Agency. Zessly 100 mg powder for concentrate for solution for infusion: summary of product characteristics. 2018. \n                    http:\/\/www.ema.europa.eu\n                    \n                  . Accessed 20 Sep 2018."},{"issue":"11","key":"310_CR2","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1007\/s12325-016-0403-9","volume":"33","author":"M Derzi","year":"2016","unstructured":"Derzi M, Johnson TR, Shoieb AM, et al. Nonclinical evaluation of PF-06438179: a potential biosimilar to Remicade\u00ae (infliximab). Adv Ther. 2016;33(11):1964\u201382.","journal-title":"Adv Ther."},{"issue":"4","key":"310_CR3","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1080\/1744666X.2018.1446829","volume":"14","author":"R Palaparthy","year":"2018","unstructured":"Palaparthy R, Udata C, Hua SY, et al. A randomized study comparing the pharmacokinetics of the potential biosimilar PF-06438179\/GP1111 with Remicade\u00ae (infliximab) in healthy subjects (REFLECTIONS B537-01). Expert Rev Clin Immunol. 2018;14(4):329\u201336.","journal-title":"Expert Rev Clin Immunol."},{"issue":"Suppl 1","key":"310_CR4","first-page":"612","volume":"77","author":"R Alten","year":"2018","unstructured":"Alten R, Tseluyko V, Hala T, et al. Efficacy, safety and immunogenicity from week 30 to week 54 in a randomised, double-blind phase III study comparing a proposed infliximab biosimilar (PF-06438179\/GP1111) with reference infliximab [abstract no. FRI0137]. Ann Rheum Dis. 2018;77(Suppl 1):612.","journal-title":"Ann Rheum Dis."},{"key":"310_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-018-1646-4","author":"SB Cohen","year":"2018","unstructured":"Cohen SB, Alten R, Kameda H, et al. A randomized controlled trial comparing PF-06438179\/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapy. Arthritis Res Ther. 2018. \n                    https:\/\/doi.org\/10.1186\/s13075-018-1646-4\n                    \n                  .","journal-title":"Arthritis Res Ther."},{"key":"310_CR6","unstructured":"Cohen S, Kivitz AJ, Tee M, et al. A randomized, double-blind phase III study comparing the efficacy, safety and immunogenicity of PF-06438179\/GP1111 (Ixifi\u2122), an infliximab biosimilar, and infliximab reference product (Remicade\u00ae) in patients with moderate to severe active RA: results from week 54 to week 78 [abstract no. 2521]. Arthritis Rheumatol. 2018;70(Suppl 10)."},{"key":"310_CR7","unstructured":"US National Institutes of Health. ClinicalTrials.gov identifier NCT02222493. 2018. \n                    https:\/\/clinicaltrials.gov\n                    \n                  . Accessed 20 Sep 2018"},{"key":"310_CR8","unstructured":"European Medicines Agency. Assessment report: Zessly (international non-proprietary name: infliximab). 2018. \n                    http:\/\/www.ema.europa.eu\n                    \n                  . Accessed 20 Sep 2018."},{"key":"310_CR9","doi-asserted-by":"crossref","unstructured":"Palaparthy R, Schmitt S, Rehman MI, et al. Incidence and impact of immunogenicity in a randomised, double-blind phase III study comparing a proposed infliximab biosimilar (PF-06438179\/GP1111) with reference infliximab. [abstract no. P554]. J Crohns Colitis. 2018;12(Suppl 1):S386.","DOI":"10.1093\/ecco-jcc\/jjx180.681"}],"updated-by":[{"DOI":"10.1007\/s40259-018-0316-z","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2018,11,15]],"date-time":"2018-11-15T00:00:00Z","timestamp":1542240000000}}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40259-018-0310-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-018-0310-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-018-0310-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,3]],"date-time":"2019-10-03T23:14:52Z","timestamp":1570144492000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40259-018-0310-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,4]]},"references-count":9,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["310"],"URL":"https:\/\/doi.org\/10.1007\/s40259-018-0310-5","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s40259-018-0316-z","asserted-by":"object"}]},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,4]]},"assertion":[{"value":"4 October 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2018","order":2,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":3,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The article PF-06438179\/GP1111: An Infliximab Biosimilar, written by Zaina T. Al-Salama","order":4,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The preparation of this review was not supported by any external funding. During the peer review process, the manufacturer of GP1111 was also offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit. Zaina T. Al-Salama is a salaried employee of Adis\/Springer, is responsible for the article content and declares no relevant conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}